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1. Introduction
  Cholera, an ancient and devastating acute diarrheal 
illness, is caused due to toxigenic Vibrio cholerae (V. 
cholerae) infection to humans (both adults and children), 
and currently is a serious global problem. The disease 
causes profuse watery diarrhea and can quickly lead to 
severe dehydration and death if treatment is not promptly 
given. An enterotoxin, called cholera toxin (CT), produced 
by toxigenic V. cholerae, is responsible for the manifestation 
of the disease cholera. V. cholerae was first identified by 
the Italian scientist Filippo Pacini, in 1854, though the 
discovery was not known until Koch (1894), who originally 
mentioned that cholera is caused due to V. cholerae 
infection. 
  The V. cholerae  includes both pathogenic and 
nonpathogenic strains, differing in their virulence gene 
contents and polysaccharide surface antigens, and thus, 
among V. cholerae, the two toxigenic serogroups O1 and 
O139 are regarded as the etiologic serogroups causing the 
disease, which can be epidemic, endemic or pandemic 
in nature. This historically-feared disease still remains a 
major public health problem in many parts of Africa, Asia 
and Latin America, and though rare in developed countries, 
it is still an important infection worldwide, and thus, 
the disease has been categorized as the “emerging and 
reemerging infection” threatening many parts in the globe. 
The current burden of cholera is estimated to reach many 
million cases a year in both Asia and Africa, with fewer 
cases in Latin America[1].
  It has been endemic in India, especially in the deltas 
of the Ganges and Brahmaputra including West Bengal, 
which has been recognized as the “homeland of V. cholerae 
causing cholera”. The World Health Organization (WHO) 
describes cholera as a global threat to public health and 
one of the key indicators of social development, stating 
that with the increased reporting of cholera in 2006, almost 
every developing country is with an outbreak or the threat 
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of an epidemic[2]. In this Review, we define various updated 
facts and phenomena related to the epidemiology of cholera, 
based upon the extensive searches in several biomedical 
science journals and web-based official organization 
reports.
2. Etiology 
2.1. Identity confirmation
  The V. cholerae is a gram-negative rod (slightly curved) 
and is characterized by the presence of a single polar 
flagellum, for which the bacterium is motile. The bacterium 
with positive oxidase reaction, 毬-haemolysis on a blood 
agar plate, growth of yellow colonies on thiosulfate citrate 
bile salts sucrose agar, susceptibility to 10 毺g and 150 毺g 
of vibriostatic agent O-129, and tolerability and intolerability 
to 1% and 10% salt solutions, respectively, has been 
defined as the V. cholerae. The biochemicl profiles for V. 
cholerae include positive tests viz., nitrate reduction, indole 
production, catalase production, citrate utilization, ornithine 
decarboxylase production and lysine decarboxylase 
production, and negative tests such as arginine dihydrolase 
production and urea hydrolysis. The evolving identity of 
choleragenic V. cholerae does not remain the same with 
continuous process of evolution, and the recent strains are 
also in the process of dynamic genetic changes[3].
2.2. Etiologic serogroup
  The V. cholerae erogroups are recognized by the 
antigenicity of the O-antigen part of the lipopolysaccharides. 
Among more than 200 O-antigen serogroups that have been 
identified and characterized, only two serogroups, O1 and 
O139, are known to cause cholera. Thus, the choleragenic V. 
cholerae is classified, on the basis of its somatic antigens (O 
antigens), into two serogroups, the V. cholerae agglutinable 
with polyvalent O1 antiserum belong to the serogroup O1, 
and the V. cholerae non-agglutinable with polyvalent O1 
antiserum belong to the serogroup non-O1. The non-O1 
V. cholerae are agglutinable by their own antisera, and 
are designated as the V. cholerae serogroup O139; other 
V. cholerae serogroups, though occasionally cause human 
illness, have not evolved into an epidemic form.
2.3. The O1 biotype and serotype
  The O1 serogroup has two biotypes, classical and El 
Tor, and two major sereotypes, Ogawa and Inaba; a third 
serotype, known as Hikojima, exists that is rare as well as 
unstable, and the Ogawa is most prevalent one.
  The cholera biotypes (classical and El Tor) are the 
distinct phenotypes that differ with respect to the severity 
of their infections, ability to survive outside the host body, 
and seasonality patterns[4]. The identity of V. cholerae O1 
classical and El Tor biotypes can be differentiated based on 
the number of traits: the El Tor, and classical biotypes are 
characterized by their sensitivity to Mukerjee El Tor phage 
5, and polymyxin B (50 IU) and Mukerjee classical phage 
IV, respectively, and among the two biotypes, only the El 
Tor is agglutinated by chicken erythrocytes and positive to 
Voges–Proskauer reaction.
  The serotype of V. cholerae O1 depends on which of the 
genes encoding somatic antigens A, B and C are expressed, 
and thus, the serotypes differ from one another only with 
respect to antigenic determinants that are found on their 
O-antigen capsule. The Ogawa and Inaba serotypes are 
positive to Ogawa and Inaba antisera, respectively, whereas 
the Hikojima is positive to both the antisera. The strains of 
the Ogawa serotype express the A and B antigens, whereas 
Inaba strains have antigenic determinants A and C, and 
the Hikojima strains contain all the three antigens A, B 
and C. These antigenic determinants play role in inducing 
host immunity, and because of the presence of common ‘A’ 
antigenic determinant, cross-immunity between serotypes 
exists; however, differences in antigenic determinants 
in the serotypes do not play role to express differences 
in phenotypic characteristics, viz., duration of infectious 
period, strength of the hosts’ immune response or recovery 
rate. 
3. Cholera pandemics
  Cholera has affected human health for many decades, 
and there is statement, found in Sanskrit, of a disease with 
symptoms resembling cholera on the Indian subcontinent 
thousands of years ago. The world has already faced seven 
cholera pandemics in the past two centuries (Figure 1). 
The first six pandemics all seem to have originated in 
Bangladesh, and are thought to be due to the infection of the 
Classical O1 biotype[5]. The seventh cholera pandemic was 
initially caused by the O1 El Tor biotype; the 0139 biotype 
appeared in 1992, and this ongoing cholera pandemic 
started, in Indonesia, in 1961 resulting in a large number of 
cholera cases as well as deaths per year[6], and continues 
to the present day. A cumulative total of 838 315 cases had 
been notified to the WHO during 2004-2008, where as 676 651
cases were reported during 2000-2004; this represents a 24% 
increase in the number of cases reported with respect to the 
cases recorded in between 2000 and 2004[7].
Figure 1. Duration and period of seven cholera pandemics.
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4. Serogroup and serotype switching among toxigenic 
V. cholerae 
4.1. Occurrence of serogroup switching 
  It has been stated that the first six pandemics of cholera 
were due to V. cholerae O1 classical biotype, and the ongoing 
seventh was due to V. cholerae O1 El Tor biotype, which 
made its appearance in 1905, in the village of El Tor, Egypt, 
and from mid-sixties this strain completely displaced the 
classical one in the globe, and thus the seventh pandemic 
has been initiated[8]. Among the two biotypes, the El Tor 
strains have better adaptability to survive in the environment 
and also in the human host. But a novel toxigenic strain, V. 
cholerae serogroup O139 (synonym Bengal), emerged in 1992, 
as a new causative agent and rapidly spread to all cholera-
endemic areas in India as well as in the neighboring 
countries[9]. 
  In the beginning, the new strain (serogroup O139) totally 
displaced, in Calcutta (currently Kolkata) and other parts 
of India, the existing V. cholerae O1, the only serogroup 
responsible for epidemics and pandemics of cholera at that 
time in Kolkata. In 1993, causing severe epidemic in the 
Indian continent, an explosive appearance of V. cholerae 
O139 occurred. The serogroup O139 disappeared soon, and 
a new clone of the El Tor biotype of O1 serogroup again 
became the major causative agent. The V. cholerae O139 
strains, in 1996, reappeared and shared with the V. cholerae 
El Tor strains of the O1 serogroup[10], suggesting the clonal 
shift in V. cholerae a basic feature of cholera dynamics. 
Currently, the El Tor V. cholerae serogroup O1 has been the 
major causative agent of the disease and the frequency of 
serogroup O139 has considerably reduced over the last few 
years. The classical biotype is believed to be extinct[11]; 
however, studies have shown that the classical CT producing 
El Tor strains (harbouring classical cholera toxin gene) 
replaced the seventh pandemic El Tor strains[12,13], and that 
the variant strain is potentially more virulent than the usual 
V. cholerae O1 El Tor[12].
4.2. Occurrence of serotype switching
  The V. cholerae O1 strains have been demonstrated to 
interconvert and to undergo serotype switching between 
Ogawa and Inaba; many authors from different parts of the 
globe reported that the emergence of V. cholerae O1 serotype 
Inaba strains were from the prevailing Ogawa stains[14,15]. In 
Kolkata, India, V. cholerae O1 Ogawa serotype predominated 
the Inaba serotype during 2004; the reverse was true for 
2005[16]. The frequency of conversion of Ogawa to Inaba 
is about 105 and the conversion of Inaba to Ogawa is rare, 
and the latter may be strain dependent, and thus, the V. 
cholerae O1 serotypes, Inaba and Ogawa, are capable of 
unequal reciprocal interconversion[8], which occur during 
epidemics or in parts where cholera is endemic. It appears 
that as an alternate to the Ogawa serotype, Inaba has 
emerged to aid the persistence of cholera, and thus the 
spread of V. cholerae O1 El Tor is continued. The serotype 
switching between Ogawa and Inaba strains has been the 
consequence of the genetic reversal occurring in vivo and in 
vitro, and is possibly mediated by the immune response in 
the population[15].
4.3. Molecular basis of the conversion 
  The serotype conversion in V. cholerae O1 might be due 
to a change in the genetic make-up of the wbeT gene (also 
known as rfbT gene that codes for O1 antigen biosynthesis), 
which occurred either by a point mutation or a deletion, 
or both, and this may occur as a result of selection due 
to pressure of lytic phages and immune response during 
cholera infection[17]. The DNA sequence analysis revealed 
that wbeT was homologous in Inaba isolates from different 
parts of India, and in all the isolates, a novel mutation 
(substitution of C for T at position 538) was detected, which 
changed serine to proline[18].
  Molecular epidemiological studies suggest that O139 
strains are closely related to O1 El Tor strains, and the O139 
strains have evolved from El Tor strains[16]; the conversion 
of the ancestral O1 El Tor strain involved insertion of a large 
foreign genomic region encoding the O139 antigen-specific 
genes and simultaneous deletion of most of the O1 antigen-
specific genes[19].
5. Cholera toxin
  The cholera toxin (CT), the primary toxin produced 
by V. cholerae O1 and O139, is responsible for most of 
the manifestations of the disease cholera. The CT is an 
oligomeric protein of 84 000 daltons, and consists of a single 
A subunit surrounded by five B subunits. Based on the B 
subunit of CT, two non identical but immunologically related 
epitypes have been designated: CT1, which is the prototype 
elaborated by classical biotype strains, and CT2, which is 
produced by the El Tor biotype and O139 strains.
  The CT causes the infected person to hypersecrete 
electrolytes and water, sometimes with fatal results. 
The B subunit of the CT is responsible for the binding 
of the holotoxin to a specific receptor, the monosialosyl 
ganglioside GM1, on mammalian intestinal mucosa cell 
membrane and facilitates entrance of the A subunit into 
the cell. The A subunit after proteolytic cleavage gives 
rise to the enzymatically active A1-peptide that catalyses 
ADP-ribosylation of the A subunit of the heterotrimeric 
GTP-binding protein Gs. This renders adenylyl cyclase 
constitutively active, thereby increasing the intracellular 
level of cAMP. This activity in turn causes secretion of 
chloride and bicarbonate into the small intestine; as a result, 
water is drawn from the intravascular and extracellular 
spaces of the body, and rapidly lost into the gut lumen.
6. Spectrum of illness
  The V. cholerae is a non-invasive organism that colonizes 
the lining epithelium of the gut after penetrating the mucus 
layer, and it affects the small intestine through the CT 
causing cholera. The hallmark of cholera is painless purging 
of very large volume of stool resembling rice-water, with 
varying degrees of dehydration that ranged from none to 
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severe and life-threatening diarrhea; the spectrum of the 
disease is thus wide, with mild and asymptomatic illness 
occurring more frequently than severe disease[20].
  The disease is characterized by incubation period 18 h 
to 5 d, followed by profuse watery diarrhea, which may be 
associated with vomiting, muscle cramps, and complications 
related to dehydration and metabolic acidosis. In its 
extreme manifestation, cholera is one of the most rapidly 
fatal infectious diseases known; within 3-4 h of the onset of 
symptoms, a healthy person may become hypotensive and 
may die within 6-8 h. More commonly, fatal cases progress 
to shock within 6-12 h with death. 
  WHO suggests that around 90 % of episodes of cholera are 
of mild to moderate severity and are difficult to distinguish 
clinically from other causes of acute diarrhea[21]. However, 
cholera can be rapidly fatal in severe cases, and if left 
untreated, can result in up to 50% mortality, but, prompt 
administration of fluid replacement and supportive therapy 
can reduce mortality to 1%[21].
7. Transmission of the disease
  Two routes of transmission of V. cholerae have been 
recognized, the first one occurs from aquatic reservoirs in 
the environment (primary transmission), and the second 
one occurs from previously infected individuals (secondary 
transmission); once the primary transmission has initiated 
an outbreak, secondary transmission causes epidemics in 
the endemic areas[22].
  In endemic areas, water is usually the main vehicle of 
transmission, although this may occur via food, and thus 
infection due to V. cholerae begins with the ingestion of 
contaminated water or food. Transmission of cholera in 
non-endemic areas is more commonly associated with 
consumption of foods, such as raw or undercooked seafood, 
imported from cholera-endemic regions.
  People infected with cholera suffer acute diarrhea 
and excrete “rice-water stool” loaded with toxigenic V. 
cholerae, which can infect water that is to be used by other 
people. Thus, the major source of V. cholerae is faeces of 
persons acutely infected with the organism that reaches 
water most often through sewage. Individuals with reduced 
gastric acidity and blood group O are more susceptible to 
the infection, and in situations where poor environmental 
sanitation is coupled with poor domestic and personal 
hygiene, transmission results from ingestion of faecally 
contaminated water (as well as food), and hence it is usually 
a disease of developing countries or areas where improved 
water and adequate sanitation are lacking.
  Person-to-person transmission of cholera is regarded 
as uncommon, and in human volunteer studies, the 
infective dose was determined to be 102-103 cells, as has 
been reported by Hartely et al[23]. However, the size of the 
inoculum needed to cause severe infection is on the basis of 
health status of the individual; a high infectious dose (105-
10
8 bacteria) is necessary to produce disease in healthy 
individuals, and a very small inoculum can also manifest 
the disease in populations with low levels of gastric acid[24]. 
Transmission via the faeces of an infected individual may 
cause the disease with small inoculum, if this occurs within 
a few hours of exposure[25].
8. Cholera epidemic and outbreak
  Epidemics or explosive outbreaks generally occur in 
underdeveloped areas with inadequate sanitation, poor 
hygiene, and limited access to safe water supplies, whereas 
in some countries, a seasonal relation for cholera epidemics 
has been observed[4,17]. WHO described a dramatic increase 
in the number of cholera cases and outbreaks[2], in the new 
communities and in communities where the disease had 
been absent for many years, with changing profiles[2], and so 
is often considered as a re-emerging disease.
  The cholera endemicity in India is the potential risk of 
epidemics, and thus outbreaks of cholera including major 
epidemics have occurred from time to time at various places 
in the country[26-28]. A total of 68 outbreaks occurred in 18 
states and union territories in India, and the overall number 
of cases was many folds higher than the number reported 
to WHO over the same time period[29], and according to 
data from population-based diarrhea surveillance, the 
incidence of cholera was 2.2 cases per 1 000 in Kolkata[30], 
the homeland of the disease that in the very first decade of 
the current century witnessed several outbreaks. Sur et al[31] 
reported an outbreak of cholera during 2004 in the eastern 
part of the city, and during 2004 and 2005, two outbreaks 
from different parts of the West Bengal state have been 
reported [32]. Mandal et al[33] reported 2007 cholera outbreak 
from Kolkata, due to the infection of multidrug resistant V. 
cholerae O1 strains.
  In the year 2006, 52 countries officially reported a large 
number of cases, with fatality rate 2.7%, to the WHO[2]. 
Tavana et al[34] investigated the relationship of duration with 
outbreaks of cholera for seven years (2000-2006) in Iran. 
MDR cholera epidemics have been reported from the India’s 
neighboring countries like Bangladesh[35], Pakistan[36] 
and Nepal[37]. In July 2002, cholera outbreak caused by V. 
cholerae O139 was detected in Karachi, Pakistan[36] and in 
March 2005, V. cholerae O139 emerged as the sole cause of 
a significant outbreak of cholera in southern costal area of 
Bangladesh[38]. WHO reported a 30% increase in cholera 
cases in 2005, compared with 2004[39], and China has 
reported that cases have increased in 2005 compared with 
2004[40].
  African countries experienced more epidemics and cases 
of cholera than countries in Asia and America, and most 
cholera cases reported to WHO originate in Africa: 95% in 
2005[39], and 94% in 2004[41]. During 2004, major outbreaks 
of cholera occurred in Cameroon, Chad, Guinea, Mali, 
Niger, Senegal, and Zambia[41]. In between August 2008 and 
February 2009, 70 640 patients were reported with cholera 
in Zimbabwe, of which 3 467 died[42], and more accurately 
the 2008-2009 cholera outbreak, which involved nearly 100 
000 people, the case fatality rate was 4.3%[43]. The Haitian 
populations have little access to safe sources of water, and 
hence remain vulnerable to epidemics of cholera [44]. In a 
current epidemic in Haiti, the case fatality rate for cholera 
remains at 6%; 18 382 hospital admissions, and 1 110 deaths 
due to cholera have been reported[45].
  Several biological factors may influence the success of V. 
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cholerae clones in cholera epidemics, including resistance 
to predation by phages, resistance to prevailing immune 
mechanisms in the human population and resistance to 
antibiotics used in the treatment[17]. The human immunity 
and the selection pressure due to lytic phages may provide 
explanation for periodic shift in the occurrence of cholera by 
V. cholerae strains of different serogroups and serotypes[17], 
while antibiotics directly influence the development of 
antibiotic resistance among the strains causing cholera 
endemic areas. Overall, the epidemics of cholera depend 
on the amplification of toxigenic V. cholerae in humans 
and their transmission by the faecal-oral route, and the 
host genetic factors (including blood group O) predispose 
individuals to severe cholera, and differ in prevalence 
between populations in endemic and non-endemic 
regions[43].
9. Treatment protocol for cholera
9.1. Rehydration therapy
  Rehydration is the essence of cholera treatment, and thus 
individual patients should be treated with appropriate 
intravenous or oral rehydration fluids; for severely 
dehydrated patients, isotonic fluids (preferably lactated 
Ringer’s solution) has preferably been suggested through 
intravenous route, until the detectable pulse is restored. 
Patients with severe cholera need 200 mL per kg of isotonic 
fluids in the first 24 h of therapy, but this amount might 
range from 100 mL per kg to more than 350 mL per kg[46]. 
Patients without severe dehydration can usually be treated 
with oral rehydration solution. The intravenous route can 
also be adopted for moderately dehydrated patients unable 
to tolerate the oral route, and for patients considered as high 
stool purgers (>10 mL/kg/h), at the time of maintenance 
phase. At the International Centre for Diarrhoeal Disease 
Research in Dhaka, Bangladesh (ICDDR, B), which played 
a crucial role in providing oral rehydration therapy, has 
extensive experience of management of severe cholera 
patients, minimizing case fatality rate below 0.2%[1,47].
9.2. Antibiotic treatment regimen
  Rehydration is the mainstay of cholera treatment, but 
antibiotics have been shown to be important in severe cases 
and in epidemic situations. The antibiotic therapy, which 
is considered as an useful adjunct to fluid replacement 
in treating cholera, can shorten the duration of diarrhea, 
and reduce stool volume and requirements for rehydration 
fluids thereby reducing the duration of hospitalization and 
breaking the transmissibility cycle in epidemic situations[48]. 
Following antibiotic therapy, Saha et al[49] and Hossain et 
al[48] reported cholera cases with shortening of the diarrhoeal 
illness course and the volume of diarrhoeal stool output by 
up to 50%.
  Tetracycline (T) and doxycycline (Dx) have long been the 
antibiotics of choice for treating severe cholera[24], and these 
were found effective when used in a single dose, except for 
young children and pregnant women. Furazolidone (Fz), 
erythromycin (Er), trimethoprim-sulphamethoxazole (Tm-
Smz), ampicillin (Am) and chloramphenicol (C) are effective 
against severe cholera caused by of V. cholerae susceptible 
to these agents; ciprofloxacin (Cp) is an important substitute 
drug for treatment of multidrug resistant (MDR) cholera. In 
children, Tm-Smz, Er and Fz are preferred, while pregnant 
women can be treated with Er or Fz[50]. The current safe 
alternatives for MDR V. cholerae with Cp resistance remain 
the third generation cephalosporins including ceftriaxone 
(Cf) and cefotaxime (Ct), which are very expensive and the 
supply is limited in poor countries; the other alternative 
includes azithromycin (Az)[51]. Cp and Az were reported to 
be more effective than Er or T, when used in single doses 
against V. cholerae infection due to the strains susceptible 
to these drugs[52]. Moreover, it has been suggested that the 
choice of antibiotic must be guided by local antibiogram 
patterns prevailing at a given time, and in order to select 
drugs in the first-line treatment options like drug efficacy, 
its current affordability, and the therapeutic ratio (which will 
be high), should also be considered. The current strain in 
circulation in Haiti is susceptible to Dx and Az and resistant 
to Nx, with reduced susceptibility to Cp; and thus prepared 
the appropriate antibiotic choice for the management of 
cholera in Haiti[43].
9.3. Combined chemotherapy 
  Combination effect of antimicrobial agents appears to be 
of particular interest in the treatment of infection caused 
by microorganisms resistant to clinically achievable 
concentration of single drug, and also in order to reduce 
the chances of emergence of drug resistance[53,54]. 
Cotrimoxazole, which is a combination of Tm and Smz, has 
been in use against the infection of different enteric bacteria 
including V. cholerae. An in vitro synergistic activity of 
CP-Tm combination against V. cholerae O1 biotype El Tor 
serotype Ogawa showing resistance to Cp an Tm suggests 
that Cp in combination with Tm could be the potential 
treatment regimen against drug-resistant cholera[55]. 
However, more studies are required to establish various 
antibiotic combinations with synergistic interation, and their 
effective in vivo application against MDR cholera.
10. Incidence of multi-drug resistance among V. 
cholerae
  Indiscriminate and rampant use of antibiotics in the 
treatment of cholera and other enteric diseases led 
emergence of antibiotic resistance among V. cholerae and 
other enteric bacteria. Multidrug resistant (MDR) V. cholerae 
with epidemic outbreaks (both classical and El Tor biotypes) 
have been reported worldwide. The profiles of major 
multiple antibiotic resistant V. cholerae as documented in 
Kolkata and other parts of India are: Am-Fz (ampicilllin- 
furazolidone), Am-Fz-Nm (Am-Fz-neomycin), Am-Fz-
Nm-Str (Am-Fz-Nm-streptomycin) [56], and Am-Tm-T-
Er-Nx (Am-trimethoprim-tetracycline-erythromycin-
nalidixic acid) Tm-T-Er-Cp (Tm-T-Er-ciprofloxacin) and 
Am-Tm-Nx[33]. Antibiotic resistance of MDR V. cholerae 
O1 biotype El Tor serotype Ogawa isolates involved in an 
outbreak of cholera in 2007, based upon the minimum 
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the globe[33,60].
11. Cholera vaccine
  A vaccine that is effective in lowering the total number 
of cases will also lower the number of resistant infections 
and could thus represent an effective intervention measure 
to control antibiotic resistance in cholera. Manna et al[61] 
reported vaccination against cholera, in conjunction with 
other prevention and control strategies, as an attractive 
additional tool to combat the disease in endemic areas. 
Page[62] described vaccines help limit epidemics in endemic 
areas where poor sanitation seems difficult to overcome. 
The injectable vaccines for cholera have been in use for 
long time, but with little lasting benefit. The currently 
available killed injectable vaccine is not recommended, 
since studies showed it to be less effective. However, the 
current availability of improved oral cholera vaccines has 
led to renewed interest in the use of vaccines during cholera 
epidemics. Ali et al[63] documented on significant herd 
immunity conferred by oral cholera vaccines in a large field 
trial in Bangladesh, and showed vaccinating more than 51% 
of the population in a geographic area led to a substantial 
reduction in cholera rates among individuals who did not 
take the vaccine.
  Two oral cholera vaccines: one consisting of killed whole-
cell V. cholerae O1 in combination with a recombinant 
B-subunit of cholera toxin (WC/rBS), and the other live 
attenuated vaccine containing the genetically manipulated 
classical V. cholerae strain CVD 103-HgR have been 
reported. Compared to the old parenteral vaccine, the 
current oral vaccines provide better and more long-lasting 
protection against cholera[64]. Mass vaccination, with WC/rBS 
vaccine, has been shown to be effective in refugee camps 
as well as in endemic regions, and a single-dose of CVD 
103-HgR vaccine was found effective to limit the spread of a 
cholera outbreak[65, 66]. However, the manufacturer stopped 
production of CVD 103-HgR vaccine in 2004, and, although 
licensed it is no longer available[39], due to reason described 
by Richie et al[67]. Thus, WC/rBS is currently the cholera 
vaccine, prequalified by WHO, providing also some cross 
protection against enterotoxigenic Escherichia coli diarrhoea, 
is the one that has been used extensively worldwide.
12. Conclusion
  Cholera is a life threatening diarrheal disease; while 
replacement of fluids and electrolytes remains the 
cornerstone of the management of cholera, antimicrobial 
therapy can significantly shorten the duration of diarrhoea, 
and reduce stool volume and requirements for rehydration 
fluids. However, like most bacteria of clinical and public 
health significance, V. cholerae O1 is continuously 
becoming more resistant to a variety of antimicrobial 
agents, necessitating the use of newer drugs which are more 
expensive and have more adverse effects to patients. In this 
situation, rotational use of anti-cholera antibiotics may lead 
to emergence of fully susceptible strains over time, which 
may allow for extension of use of the most effective therapies 
such as T as well as Cp.
  The diversity of V. cholerae serogroups potential to cause 
cholera might be the survival advantage to the V. cholerae 
strains in the wake of host with less susceptibility to the 
pathogen. These strains, along with MDR clones, may form 
a group of emerging pathogens. Since the epidemics caused 
by the infection of MDR strains remain a threat, effective 
antibiotics are needed to reduce costs and treatment time, 
shorten the duration of illness; the antibiotic resistance 
patterns that change from time to time and place to place 
also require continual surveillance in order to provide 
inhibitory concentration determination following National 
Committee for Clinical Laboratory Standards guidelines, 
are represented in Table 1. It has been reported worldwide 
that there is great variation in antibiotic resistance among 
V. cholerae O1 strains[26-28]. Overall, the V. cholerae strains 
limit the therapeutic potential of antibiotics: some antibiotics 
are already unsuitable for certain group of population (such 
as T is not recommended for children and quinolones are not 
for pregnant women and children); the multi-drug resistance 
on the other hand presents additional challenges to disease 
management. Thus, multiple antibiotic resistances among V. 
cholerae have emerged as a major problem worldwide[57].
  Plasmids are known to encode and transfer resistance 
in V. cholerae. Prescott and his colleagues (1968) reported 
the discovery of transferable R-plasmid in MDR V. 
cholerae isolated in Calcutta (Kolkata), India. Transfer 
of antimicrobial resistance has been documented among 
various serogroups of V. cholerae, and also between V. 
cholerae and the members of the family Enterobacteriaceae. 
Plasmid encoded resistance to Am-C-Str-Smz-Tr has 
been reported among V. cholerae O1 isolates from eastern 
Africa[58]. Plasmid mediated resistance to Tm-Smz-C-Am-
Str in outbreak causing V. cholerae in Tanzania has been 
reported by Reid and Amyes[59]. The V. cholerae strains with 
plasmid, of different sizes, encoding multidrug resistance of 
various patterns have been reported from different parts of 
Table 1
Minimum inhibitory concentration (MIC) values of antibiotics for outbreak causing V. cholerae O1 biotype El Tor serotype Ogawa isolates in 
Kolkata, India.
Strains
MICs of antibiotics (毺g/mL)
Am C Tm T Er Nx Cp Ak Cfx
Resistant isolates 75-200 - 75-200 75-100 64-128 32-64 10 - -
Sensitive isolates       2-4 2-8 - 4 2 4-8 0.66 2-4 2-8
Am = ampicillin, Ak = amikacin, C = chloramphenicol, Cfx = cefotaxime, Cp = ciprofloxacin, Er = erythromycin, Nx = nalidixic acid, Tm = 
trimethoprim, T = tetracycline.
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appropriate treatment.
  Moreover, the continuous changes in the characteristics 
of the toxigenic V. cholerae, either in the serogroups 
predominating in outbreaks, antimicrobial resistance 
patterns, or its virulence, need monitoring of treatment 
and control of the disease. Compared with the parenteral 
vaccine, the new internationally available oral vaccines 
represent significant improvement in terms of protective 
efficacy, duration of protection, safety and easy method of 
administration.
  Over all, the most useful measure in preventing the spread 
of cholera is the provision of safe drinking water, good 
food hygiene, and sanitary disposal of human feces; also, 
vaccination and improved sanitation have synergistic roles 
in controlling the disease[24]. Thus, the global reduction of 
the burden of cholera as a human health problem requires 
a multifactorial (both international and national) action to 
improve public health and to reduce the susceptibility to the 
infection of the poor communities, and thus, to reduce the 
threat of this global problem.
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